[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares. The shares are scheduled for an approximate sale date of 08/15/2025 through Morgan Stanley Smith Barney LLC and carry an aggregate market value of $7,866,267.50. The filing reports 21,688,772 shares outstanding, meaning the proposed sale represents a small fraction of total shares. The 91,000 shares were acquired on 11/19/2021 in exchange for convertible preferred shares and were paid for in cash on the acquisition date. No other sales in the prior three months were reported.
- Clear compliance disclosure: The filer provides required Rule 144 details including broker, acquisition date, basis of acquisition, aggregate market value, and approximate sale date.
- None.
Insights
TL;DR: Insider plans to sell 91,000 ANIP shares (~$7.87M) acquired via convertible preferreds in 2021; filing follows Rule 144 disclosure requirements.
The Form 144 discloses a proposed sale executed through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/15/2025. The position was originally acquired on 11/19/2021 via convertible preferred shares and paid in cash, which is relevant for determining resale eligibility under Rule 144. The disclosed aggregate market value ($7.87M) and the stated shares outstanding (21,688,772) allow market participants to gauge the sale's relative size; the sale represents a modest percentage of outstanding shares.
TL;DR: The filer provided required attestation and signature language; no undisclosed material information is claimed.
The filing includes the standard attestation that the seller is not aware of any undisclosed material adverse information about the issuer and notes the Rule 10b5-1 trading plan language if applicable. The submission identifies the broker and confirms there were no related sales in the prior three months. From a governance and disclosure standpoint, the filing appears procedurally complete for a Rule 144 notice.